Pyronaridine

• CAT Number: I008930
• CAS Number: 74847-35-1
• Molecular Formula: C29H32ClN5O2
• Molecular Weight: 518.058
• Purity: ≥95%
• Synonyms: Pyronaridine; Malaridine; Benzonaphthyridine 7351.;2-Methoxy-7-chloro-10-(3/’,5/’-bis(pyrrolin-1-ylmethyl)-4/’-hydroxyphenylamino)benzo(b)-1,5-naphthyridine
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 4-[(7-chloro-2-methoxy-1,5-dihydrobenzo[b][1,5]naphthyridin-10-yl)imino]-2,6-bis(pyrrolidin-1-ylmethyl)cyclohexa-2,5-dien-1-one
• InChI: InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,32-33H,2-5,10-13,17-18H2,1H3
• InChIKey: YFYLPWJKCSESGB-UHFFFAOYSA-N
• SMILES: COC1=CC=C2C(=C(C3=C(N2)C=C(C=C3)Cl)N=C4C=C(C(=O)C(=C4)CN5CCCC5)CN6CCCC6)N1

Pyronaridine(CAT: I008930), known as Malaridine, is an antimalarial drug. It was first synthesized in 1970 and has been in clinical use in China since the 1980s. It is one of the components of the artemisinin combination therapy pyronaridine artesunate (Pyramax). Pyronaridine is a promising agent against the erythrocytic stage of malaria parasites. It exhibited low toxicity and had no cross-resistance to chloroquine. Clinical administration in malaria cases showed high efficacy and mild side effects.

Reference

1:pH, redox and photothermal Tri-responsive DNA/polyethylenimine conjugated gold nanorod as nanocarrier for specific intracellular Co-release of doxorubicin and chemosensitizer pyronaridine to combat multidrug resistant cancer. Wang Y, Zhang Z, Xu S, Wang F, Shen Y, Huang S, Guo S.Nanomedicine. 2017 Feb 6. pii: S1549-9634(17)30016-3. doi: 10.1016/j.nano.2017.01.014. [Epub ahead of print] PMID: 28185939 2:Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Leang R, Canavati SE, Khim N, Vestergaard LS, Borghini Fuhrer I, Kim S, Denis MB, Heng P, Tol B, Huy R, Duparc S, Dondorp AM, Menard D, Ringwald P.Antimicrob Agents Chemother. 2016 Jun 20;60(7):3884-90. doi: 10.1128/AAC.00039-16. Print 2016 Jul. PMID: 26926629 Free PMC Article3:The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine. Madamet M, Briolant S, Amalvict R, Benoit N, Bouchiba H, Cren J, Pradines B; French National Centre for Imported Malaria Study Group..Parasit Vectors. 2016 Feb 9;9:77. doi: 10.1186/s13071-016-1358-z. PMID: 26858119 Free PMC Article4:Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients. Ayyoub A, Methaneethorn J, Ramharter M, Djimde AA, Tekete M, Duparc S, Borghini-Fuhrer I, Shin JS, Fleckenstein L.Antimicrob Agents Chemother. 2015 Dec 14;60(3):1450-8. doi: 10.1128/AAC.02004-15. PMID: 26666916 Free PMC Article5:Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé AF, Coulibaly AS, Traore OB, Dara N, Kabore MJ, Thera I, Compaore YD, Sylla MM, Nikiema F, Diallo MS, Dicko A, Gil JP, Borrmann S, Duparc S, Miller RM, Doumbo OK, Shin J, Bjorkman A, Ouedraogo JB, Sirima SB, Djimdé AA.Lancet Infect Dis. 2016 Feb;16(2):189-98. doi: 10.1016/S1473-3099(15)00318-7. Epub 2015 Oct 23. PMID: 26601738 Free PMC Article6:Pyronaridine-artesunate retreatment for malaria. Bélard S, Kurth F.Lancet Infect Dis. 2016 Feb;16(2):136-7. doi: 10.1016/S1473-3099(15)00353-9. Epub 2015 Oct 23. No abstract available. PMID: 26601737 Free Article7:Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Pascual A, Madamet M, Briolant S, Gaillard T, Amalvict R, Benoit N, Travers D, Pradines B; French National Reference Centre for Imported Malaria Study Group..Malar J. 2015 Feb 5;14:49. doi: 10.1186/s12936-015-0586-6. PMID: 25848972 Free PMC Article8:Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, Thana P, Chairat K, Blessborn D, Panapipat S, White NJ, Day NP, Tarning J.Antimicrob Agents Chemother. 2015 Jan;59(1):505-13. doi: 10.1128/AAC.03829-14. Epub 2014 Nov 10. PMID: 25385096 Free PMC Article9:Comparison of hematin-targeting properties of pynacrine, an acridine analog of the benzonaphthyridine antimalarial pyronaridine. Sereekhajornjaru N, Somboon C, Rattanajak R, Denny WA, Wilairat P, Auparakkitanon S.Acta Trop. 2014 Dec;140:181-3. doi: 10.1016/j.actatropica.2014.09.002. Epub 2014 Sep 16. PMID: 25220507 10:Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol. Morris CA, Pokorny R, Lopez-Lazaro L, Miller RM, Arbe-Barnes S, Duparc S, Borghini-Fuhrer I, Shin JS, Fleckenstein L.Antimicrob Agents Chemother. 2014 Oct;58(10):5900-8. doi: 10.1128/AAC.02716-14. Epub 2014 Jul 28. PMID: 25070091 Free PMC Article